ASX-listed consumer healthcare company Wellnex Life Ltd has obtained an additional quotation on AIM. This will help it to finance growth outside of Australia.
The company has a range of its own brands and an agreement with Haleon to sell Panadol products. There are already significant revenues in Australia and potential in other markets, such as the UK and UAE.
On the first day of trading the share price was 31p, but it has declined since then. It has bottomed out at 24p, which is well below the flotation price. A loss is forecast for this year, but the shares are trading on a potential...
